The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor

被引:35
作者
Sahlholm, Kristoffer [1 ]
Zeberg, Hugo [1 ]
Nilsson, Johanna [1 ]
Ogren, Sven Ove [1 ]
Fuxe, Kjell [1 ]
Arhem, Peter [1 ]
机构
[1] Karolinska Inst, Dept Neurosci, Retzius Vag 8, SE-17177 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Isleuroleptics; Electrophysiology; Extrapyramidal rigidity; Dopamine antagoists; Oocytes; ATYPICAL ANTIPSYCHOTICS; SEROTONIN RECEPTORS; FAST DISSOCIATION; SCHIZOPHRENIA; AGONIST; BINDING; PSYCHOSIS; CHANNELS; LIGANDS; DRUGS;
D O I
10.1016/j.euroneuro.2016.01.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Newer, "atypical" antipsychotics carry a lower risk of motor side-effects than older, "typical" compounds. It has been proposed that a 100-fold faster dissociation from the dopamine D-2 receptor (D2R) distinguishes atypical from typical antipsychotics. Furthermore, differing antipsychotic D2R affinities have been suggested to reflect differences in dissociation rate constants (k(off)), while association rate constants (k(on)) were assumed to be similar. However, it was recently demonstrated that lipophilic accumulation of ligand in the cell interior and/or membrane can cause underestimation of koff, and as high-affinity D2R antagonists are frequently lipophilic, this may have been a confounding factor in previous studies. In the present work, a functional electrophysiology assay was used to measure the recovery of dopamine-mediated D2R responsivity from antipsychotic antagonism, using elevated concentrations of dopamine to prevent the potential bias of re-binding of lipophilic ligands. The variability of antipsychotic kon was also reexamined, capitalizing on the temporal resolution of the assay. kon was estimated from the experimental recordings using a simple mathematical model assumed to describe the binding process. The time course of recovery from haloperidol (typical antipsychotic) was only 6.4- to 2.5-fold slower than that of the atypical antipsychotics, amisulpride, clozapine, and quetiapine, while antipsychotic kons were found to vary more widely than previously suggested. Finally, affinities calculated using our kon and koff estimates correlated well with functional potency and with affinities reported from radioligand binding studies. In light of these findings, it appears unlikely that typical and atypical antipsychotics are primarily distinguished by their D2R binding kinetics. (C) 2016 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:467 / 476
页数:10
相关论文
共 28 条
[11]   Pharmacology of JNJ-37822681, a Specific and Fast-Dissociating D2 Antagonist for the Treatment of Schizophrenia [J].
Langlois, Xavier ;
Megens, Anton ;
Lavreysen, Hilde ;
Atack, John ;
Cik, Miroslav ;
te Riele, Paula ;
Peeters, Luc ;
Wouters, Ria ;
Vermeire, Jef ;
Hendrickx, Herman ;
Macdonald, Gregor ;
De Bruyn, Marcel .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 342 (01) :91-105
[12]   COMPARISON OF INVITRO BINDING-PROPERTIES OF A SERIES OF DOPAMINE ANTAGONISTS AND AGONISTS FOR CLONED HUMAN DOPAMINE D2S-RECEPTORS AND D2L-RECEPTORS AND FOR D2-RECEPTORS IN RAT STRIATAL AND MESOLIMBIC TISSUES, USING [I-125] 2'-IODOSPIPERONE [J].
LEYSEN, JE ;
GOMMEREN, W ;
MERTENS, J ;
LUYTEN, WHML ;
PAUWELS, PJ ;
EWERT, M ;
SEEBURG, P .
PSYCHOPHARMACOLOGY, 1993, 110 (1-2) :27-36
[13]   Phasic Dopamine Release Drives Rapid Activation of Striatal D2-Receptors [J].
Marcott, Pamela F. ;
Mamaligas, Aphroditi A. ;
Ford, Christopher P. .
NEURON, 2014, 84 (01) :164-176
[14]  
Meltzer HY, 2012, CURR PHARM BIOTECHNO, V13, P1572
[15]   Serotonin receptors : their key role in drugs to treat schizophrenia [J].
Meltzer, HY ;
Li, Z ;
Kaneda, Y ;
Ichikawa, J .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (07) :1159-1172
[16]   Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and Schizoaffective disorder [J].
Meltzer, HY ;
Arvanitis, L ;
Bauer, D ;
Rein, W .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (06) :975-984
[17]   Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents [J].
Miyamoto, S. ;
Miyake, N. ;
Jarskog, L. F. ;
Fleischhacker, W. W. ;
Lieberman, J. A. .
MOLECULAR PSYCHIATRY, 2012, 17 (12) :1206-1227
[18]   Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach [J].
Packeu, A. ;
Wennerberg, M. ;
Balendran, A. ;
Vauquelin, G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (06) :1311-1328
[19]   Synthesis and Evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D2 Receptor Ligands and the Discovery of the Dopaminergic Stabilizer 4[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16) [J].
Pettersson, Fredrik ;
Ponten, Henrik ;
Waters, Nicholas ;
Waters, Susanna ;
Sonesson, Clas .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2510-2520
[20]   Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor [J].
Pompeu, Thais Emanoelle T. ;
do Monte, Fernando Monteiro ;
Bosier, Barbara ;
Fraga, Carlos A. M. ;
Barreiro, Eliezer J. ;
Menegatti, Ricardo ;
Hermans, Emmanuel ;
Noel, Francois .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 62 :1-6